La vendita allo scoperto per Novavax dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Novavax. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Novavax (NASDAQ:NVAX) Azioni, Report sulle vendite allo scoperto

Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Novavax Inc

<a href="https://qz.com/fda-peter-marks-rjk-vaccines-1851705107">https://qz.com/fda-peter-marks-rjk-vaccines-1851705107</a>
The U.S. Food and Drug Administration's (FDA) head of vaccine safety says that President-elect Donald Trump's embrace of vaccine skeptics could be an opportunity for the science community to teach the public about the value of these life-saving drugs. However, if these efforts fail it could lead to "natural consequences."
The FDA's Peter Marks made the remarks Thursday at the Jefferies London Healthcare Conference. Marks is the current director of the Center for Biologics Evaluation and Research (CBER) at the FDA. The center ensures the safety and effectiveness of biological products, including vaccines.
Marks said now is the chance for scientists to make the case for vaccines, as Trump has named noted anti-vaccine crusader Robert F. Kennedy Jr. as his pick to be the next Secretary of Health and Human Services.
Bloomberg is also reporting that Trump is likely to pick surgeon and public health researcher Marty Makary as the next head of the FDA. Previously, Makary has criticized the agency's approval of COVID-19 booster vaccines. Additionally, he has written several op-eds on the pandemic including one claiming that the U.S. would achieve <a href="https://www.wsj.com/articles/well-have-herd-immunity-by-april-11613669731">herd immunity by April 2021 </a>and a more recent one arguing that vaccines shouldn't be <a href="https://www.wsj.com/articles/biden-waves-another-covid-shot-through-fda-human-outcomes-data-195731c0">recommended universally</a> for lower-risk patients.
Marks said that if public health officials fail to make the case for vaccines there will be consequences.
"If that doesn't work, and everything runs wild in the opposite direction, just as your kids learn natural consequences — if you put your hand on a hot oven, you will get burned, et cetera, that kind of thing — the American public will learn the natural consequences of what happens if vaccination rates fall too far, because we will start to see measles, polio, things that we should never see in a well-developed country, come back," said Marks, who was speaking virtually at the conference, <a href="https://www.statnews.com/2024/11/21/peter-marks-fda-rfk-jr-vaccine-safety/">STAT reported</a>.
Marks said he expects a vigorous debate on COVID-19 vaccines and pediatric vaccines but hopes a "degree of moderation will prevail" on the topic of vaccines overall.

News

Trading Ideas

BNTX

MRNA

NVAX

Watching Shares Of Vaccine Stocks; Traders Circulate Article Titled "Top FDA vaccine official says RFK Jr. nomination is a chance for scientist to make the case for vaccines"

<a href="https://www.cdc.gov/ncird/whats-new/reduce-your-risk-from-respiratory-viruses-this-holiday-season.html" title="https://www.cdc.gov/ncird/whats-new/reduce-your-risk-from-respiratory-viruses-this-holiday-season.html">https://www.cdc.gov/ncird/whats-new/reduce-your-risk-from-respiratory-viruses-this-holiday-season.html</a>

Biotech

General

U.S. CDC Says Flu, Covid-19, RSV Illnesses Are At Low Levels Right Now Overall In U.S., But We Expect Them To Increase In Coming Weeks; Expects Hospitalizations For Flu And Covid-19 To Start Increasing In Coming Weeks

<a href="https://www.cdc.gov/bird-flu/spotlights/h5n1-response-11152024.html" title="https://www.cdc.gov/bird-flu/spotlights/h5n1-response-11152024.html">https://www.cdc.gov/bird-flu/spotlights/h5n1-response-11152024.html</a>

U.S. CDC Says Since April Confirmed Avian Influenza A(H5) Virus Infections In 52 People In US; Aware Of Human Case Of H5N1 Bird Flu Reported In Canada & Is In Communication With Public Health Agency Of Canada

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/11/2024-11-15_08h38_46.png" alt="" style="width:624px" /></figure>
<h3 class="wp-block-heading">Powell Speaks The Truth</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-powell-speech-trump-appointments-spy-mc-11152024">click here</a> for an enlarged chart of SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul>
<li>It is worth a reminder that The Arora Report is politically agnostic.&nbsp; Our sole job is to help our members extract the maximum amount of money out of the markets with the least possible risk.</li>
<li>The price action on the chart shows that the rip roaring Trump rally is taking a breather.</li>
<li>The chart shows that the stock market is still above the breakout line.</li>
<li>RSI on the chart shows that the stock market has pulled back, reflecting a loss of momentum. The stock market is still overbought.</li>
<li>The chart shows that the volume remains low.&nbsp; This indicates that institutional investors are not rushing to buy stocks.</li>
<li>Yesterday, Powell spoke that truth – the market did not like it.&nbsp; Powell said, "The economy is not sending any signals that we need to be in a hurry to lower rates."&nbsp; Powell elaborated, "The strength we are currently seeing in the economy gives us the ability to approach our decisions carefully."</li>
<li>Powell's remarks brought some selling into stocks and bonds.</li>
<li>This morning, in the early trade, selling continues.</li>
<li>The reason for some selling is that the prevailing wisdom on Wall Street has been that another rate cut in December was a sure thing.&nbsp; The Arora Report has been questioning Wall Street's wisdom and sharing with you that the data does not support another rate cut.</li>
<li>Some conservative commentators are upset believing that the reason Powell started rate cuts with a 50 bps cut was to help Kamala Harris get elected.&nbsp; Now that Trump has been elected, Powell is in no hurry to cut rates.</li>
<li>In The Arora Report analysis, even though the data does not support a rate cut in December, Powell is going to feel pressure from Trump and Republicans to cut rates.&nbsp; There is also a significant amount of data between now and the December Fed meeting.</li>
<li>In The Arora Report analysis, based on a 360 degree view, including the political pressure and the pressure from Wall Street to cut rates, the probability of a rate cut in December is now about 60%.&nbsp;&nbsp;</li>
<li>There is consternation about several Trump picks.&nbsp; Impacting the market most are Trump's picks of RKF Jr, Matt Gaetz, and Pete Hegseth.&nbsp; These picks are bringing selling in vaccine makers such as Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), BioNTech SE ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).&nbsp; There is also selling in other healthcare stocks, including weight loss drug companies Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and packaged food stocks such as The Kraft Heinz Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>).&nbsp; There is also selling in defense stocks such as Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), Northrop Grumman Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), and Rtx Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>).&nbsp; There is also selling in big tech stocks.</li>
<li>The latest economic data is strong.&nbsp; The U.S. economy is about 70% consumer based.&nbsp; For this reason, prudent investors pay attention to retail sales.&nbsp; Here are the details of the just released data:
<ul>
<li>Retail sales came at 0.4% vs. 0.3% consensus.</li>
<li>Retail sales ex-auto came at 0.1% vs. 0.2% consensus.</li>
</ul>
</li>
<li>There are hundreds of indicators.&nbsp; At The Arora Report, the system has been refined through decades of research to share with you only those indicators that matter.&nbsp; Normally, we do not mention the NY Fed Empire State Manufacturing Index.&nbsp; Today, we are mentioning it due to its exceptional strength.&nbsp; The index came at 31.2 vs. 3.3 consensus.&nbsp; This indicates that manufacturing in the New York area has picked up steam. &nbsp; If similar strength is happening in the rest of the country, that would argue against further cutting interest rates. The problem for investors is that stock valuations are so high that to sustain them, rate cuts are needed.&nbsp;&nbsp;</li>
</ul>
<h3 class="wp-block-heading">Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are negative in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
In the early trade, money flows are negative in S&amp;P 500 ETF (SPY) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h3 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).  The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).  The most popular ETF for oil is United States Oil ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>).
<h3 class="wp-block-heading">Bitcoin</h3>
Even the slightest dips in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) are being bought.
<h3 class="wp-block-heading">Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3 class="wp-block-heading">Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Politics

Federal Reserve

Markets

$BTC

AAPL

AMZN

GOOG

MSFT

NVDA

TSLA

Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth

WIIM

PCVX

Shares of vaccine stocks are trading lower After President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.

The World Health Organization (WHO) on Friday described vaccines as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived childhood without them. This comes at after Donald Trump&#8216;s announcement of Robert F. Kennedy Jr. as Health Secretary.
What Happened: As per <a href="https://pro.benzinga.com">Benzinga Pro</a> on Friday, health stocks declined further during pre-market hours. Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) saw a 0.58% drop after closing 2.62% lower at $26.02. Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) was down by 1.56% while AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) fell by 1.41%, and Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) decreased by 1.39%, having already dropped 7.02% to $7.22.
While the spokesperson for WHO did not comment on Kennedy Jr&#8217;s appointment directly, she mentioned that the U.S. is an important United Nations member and hoped the &#8220;fantastic work&#8221;&nbsp; would continue, <a href="https://www.bbc.com/news/live/c0lp93494g9t?post=asset%3Afdf8e84f-8eb1-45b0-9e05-4ad5adad709b#post">as</a> per BBC news.
Trump&#8217;s decision to appoint Kennedy, known for his vaccine skepticism and conspiracy theories has sparked significant attention. The move aligns with Kennedy&#8217;s recent endorsement of Trump after ending his presidential bid.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Thank you <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> for your leadership and courage. I&#39;m committed to advancing your vision to Make America Healthy Again. We have a generational opportunity to bring together the greatest minds in science, medicine, industry, and government to put an end to the chronic…
&mdash; Robert F. Kennedy Jr (@RobertKennedyJr) <a href="https://twitter.com/RobertKennedyJr/status/1857198805919138235?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41947492/syros-pharmaceuticals-stock-sinks-as-pivotal-blood-cancer-trial-flunks-triggers-loan-default?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default</a>
Why It Matters: The appointment of Kennedy, a prominent critic of vaccines, as Health Secretary could signal a shift in national health policies. Trump&#8217;s choice has <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">elicited mixed reactions</a>, particularly among public health experts. Kennedy&#8217;s stance on vaccines may influence future health regulations and policies.
Kennedy&#8217;s views on vaccines <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">and health agencies diverge sharply</a> from mainstream medical consensus. He has consistently propagated debunked claims, including the false assertion that vaccines cause autism—a theory discredited by extensive scientific research. His nomination for HHS secretary comes amid declining vaccination rates, which have contributed to public health challenges such as 13 measles outbreaks reported in the U.S. this year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">AbbVie&#8217;s Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio</a></li>
</ul>
Image via Shutterstock

Health Care

Pre-Market Outlook

WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill

U.S. stocks could open on a negative note on Friday after the Federal Reserve chair Jerome Powell's <a href="https://www.benzinga.com/news/econ-s/24/11/41991849/powell-with-strong-us-economy-fed-has-no-need-to-be-in-a-hurry-to-lower-rates">comments on Thursday</a> that the economy is showing enough strength that there is no need to be "in a hurry" on further rate cuts just yet.
Futures of all three major indices were down as investors processed crucial inflation and economic data released over the week.
"The economy is not sending any signals that we need to be in a hurry to lower rates. The strength we are currently seeing in the economy gives us the ability to approach our decisions carefully," Powell said, maintaining a wait-and-watch approach for the time being.
For now, the post-election rally in the equity markets seems to be slowing down as investors hedge their bets while booking some profits at the same time.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.89%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.63%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.43%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.29%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) edged lower by 0.53% to $590.22 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) declined 0.80% to $504.63, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks ended Thursday in the red, with the tech-heavy Nasdaq falling the most.
Crude oil prices remained under the $70 mark, easing further on Friday due to fears of a slowdown in China resulting in lower demand.
Treasury yields edged up again as investors digested Powell's comments on the economy as well as rate cuts in the near future.
On the economic data front, U.S. initial jobless claims declined by 4,000 from the previous week to 217,000 in the week ending Nov. 9, compared to market estimates of 223,000.
The U.S. producer prices rose 0.2% month-over-month in October compared to a revised 0.1% gain in September, which is in line with market expectations.
Most sectors on the S&amp;P 500 closed on a negative note, with consumer discretionary, industrials, and healthcare stocks recording the biggest losses on Thursday.
However, information technology and energy stocks bucked the overall market trend, closing the session higher.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.64%</td>
<td>19,107.65</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.60%</td>
<td>5,949.17</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.47%</td>
<td>43,750.86</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.37%</td>
<td>2,336.94</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Powell's relatively hawkish tone has investors cautious in the markets, noted ING analyst Francesco Pesole.
This could result in a correction for the dollar, which is "testing the limit" of its longs, Pesole noted, adding that traders should exercise caution for the time being.
"Powell seemed to put greater emphasis on the strength of the economy&nbsp;and how that allows the central bank to approach the upcoming policy decisions ‘carefully'."
CME Group's FedWatch tool <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">reflected</a> the fall in sentiment for another rate cut next month, with its probability declining to 62.1% from 72.2%.
Investors will also keep an eye on the retail sales data that is set to be released later today.
However, Sonu Varghese, global macro strategist at Carson Group, downplayed fears of a rebound in inflation, stating that there are "disinflationary trends" that will "likely keep a lid" on a rise in prices.
On the equity front, Varghese maintained his bullish outlook.
"Overall, economic strengths clearly outweigh areas of weakness, and the opportunities likely have a higher probability of coming to fruition than the threats. The balance favors continued strength for equities, which is why we're maintaining our overweight to stocks, especially US stocks."
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
Friday's major economic updates include:
<ul>
<li>Import Price Index, which will be released at 8:30 a.m. ET.</li>
<li>Retail sales data, which will be released at 8:30 a.m. ET</li>
</ul>
Stocks In Focus:
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stock will be <a href="https://www.benzinga.com/24/11/41998621/palantir-moderna-pfizer-alibaba-tesla-why-these-5-stocks-are-on-investors-radars-today">in focus today</a> after reports emerged that President-elect Donald Trump is likely to end the $7,500 tax credit. Tesla shares fell 5.8% on Thursday.</li>
<li>Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) shares were up 0.4% in premarket trading after the U.S. government finalized a $6.6 billion subsidy for the chipmaker under the CHIPS Act.</li>
<li>Domino's Pizza Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) shares surged over 7% in premarket trading after Warren Buffett-led Berkshire Hathaway <a href="https://www.benzinga.com/24/11/42002180/why-dominos-pizza-shares-are-trading-higher-by-around-8-here-are-20-stocks-moving-premarket">picked up a small stake</a> in the company.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), and Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">stocks fell after Trump appointed</a> Robert F. Kennedy Jr. as the head of the Department of Health and Human Services.</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) announced it will switch from the New York Stock Exchange to the Nasdaq on Nov. 26.</li>
<li>Investors are awaiting earnings results from Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Spectrum Brands Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>), and RLX Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures fell in the early New York session, declining by 1.11% to hover around $67.94 per barrel.
The 10-year Treasury note yield edged up about to 4.43%.
Most of the major Asian markets were mixed on Friday, but European markets were marginally in the green in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></li>
</ul>
Photo courtesy: Wikimedia

Earnings

Equities

Futures

Economics

Movers

BABA

PLTR

US Stocks Likely To Open In Red After Jerome Powell Says No Need To Be 'In A Hurry' On Rate Cuts: Tesla, TSMC And Domino's In Focus

President-elect Donald Trump picked Robert F. Kennedy Jr., known for his vaccine skepticism, as his nominee Thursday to lead the <a href="https://www.benzinga.com/general/biotech/24/10/41127143/us-hhs-reveal-cost-savings-for-54-prescription-drugs-including-novartis-cancer-drug-ozempic-could">Department of Health and Human Services. </a>
This move, which comes after Kennedy ended his presidential campaign and endorsed Trump, positions the environmental activist to potentially reshape national health policies. The selection has stirred mixed reactions, particularly from public health experts, <a href="https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617">Politico</a> reports.
&#8220;For too long, Americans have been crushed by the industrial food complex and drug companies who have engaged in deception, misinformation, and disinformation when it comes to Public Health,&#8221; Trump said in a tweet announcing the decision. 
As Benzinga reported earlier this month, Kennedy has a history of spreading falsehoods about vaccines, including that they cause autism, a theory disproven by scientific studies. His selection as the nominee for HHS secretary comes against a backdrop of falling vaccination rates, which coincide with, in one example, 13 measles outbreaks in the U.S. so far this year. 
What Happened: Trump's decision is part of a broader promise to "let Kennedy go wild" with health and food policies, aiming to overhaul the HHS. Kennedy has expressed sharp criticisms of several health agencies.
Kennedy had hinted at the potential role of "health czar" in Trump&#8217;s administration. If he is confirmed, Kennedy's appointment could influence vaccine policy and the <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">direction of the CDC, FDA, and NIH.</a>
Also Read: <a href="https://www.benzinga.com/trading-ideas/24/11/41977313/will-trumps-election-win-push-sp-500-even-higher-in-final-weeks-of-2024-over-75-say">Will Trump&#8217;s Election Win Push S&amp;P 500 Even Higher In Final Weeks Of 2024? Over 75% Say&#8230;</a>
Kennedy's prospective role has already affected vaccine manufacturer stocks. Major vaccine-related companies saw declines in stock prices on Thursday due to the uncertainty surrounding Kennedy&#8217;s influence on health policy.
Key companies impacted include:
<ul>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) down 5.62% to $39.77.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) down 2.62% to $26.02.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) down 0.89% to $151.87.</li>
<li>AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) down 0.38% to $65.04.</li>
<li>Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) down 7.02% to $7.22.</li>
</ul>
Why It Matters: Kennedy's views on vaccines and health oversight agencies stand in stark contrast to established medical consensus. His appointment could alter public health directives, with some analysts predicting potential shifts in FDA regulatory independence and vaccine guidelines. 
The impact may extend beyond policy, shaping public trust in health systems amid ongoing debates over vaccine safety.
Kennedy, while indicating he has no plans to "take away anybody's vaccines," continues to be a polarizing figure. Vaccine-related stocks may experience ongoing volatility as the Trump administration finalizes its health policy agenda.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock.

Government

Regulations

Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower

<a href="https://x.com/DonaldJTrumpJr/status/1857168002837352564" title="https://x.com/DonaldJTrumpJr/status/1857168002837352564">https://x.com/DonaldJTrumpJr/status/1857168002837352564</a>

Donald Trump Jr. Posts On X "Robert F Kennedy Jr will be The Secretary of Health and Human Services! Promises Made Promises Kept"

Shares of vaccine stocks are trading lower following a report suggesting president-elect Trump is expected to nominate Robert F. Kennedy Jr. to lead the HHS.

<a href="https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617">https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617</a>
&nbsp;
President-elect Donald Trump is expected to nominate former presidential candidate and anti-vaccine activist Robert F. Kennedy Jr. to lead the Department of Health and Human Services, according to a person with direct knowledge of the selection.
The expected pick, which will roil many public health experts, comes after Trump promised to let Kennedy <a href="https://www.politico.com/video/2024/10/28/trump-says-he-would-let-rfk-jr-go-wild-on-medicines-1466853">"go wild" with health</a> and food policy in his administration after Kennedy dropped his own presidential bid to endorse the now-president-elect. It's also a sign of the opening Trump sees after he scored a decisive electoral victory and Republicans won a comfortable majority in the Senate.
Trump could still select someone else for the post. The Trump transition couldn't immediately be reached for comment.
"He's going to help make America healthy again. … He wants to do some things, and we're going to let him get to it," Trump said in his victory speech. "Go have a good time, Bobby."

'Trump Expected To Select Robert F. Kennedy Jr. To Lead HHS; The Choice Will Roil Many Public Health Experts After His Years Of Touting Debunked Claims That Vaccines Cause Autism' - Politico

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Buy and maintains $19 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Novavax, Maintains $19 Price Target

On Tuesday,&nbsp;Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>)&nbsp;reported third-quarter 2024 sales of $84.5 million, compared to&nbsp;$186.99 million&nbsp;a year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $65.78 million</a>.
Product sales of $38 million for the third quarter of 2024 were primarily related to U.S. market commercial sales. Licensing, royalties, and other revenue of $46 million in the third quarter of 2024 related to a combination of activities under the Sanofi Agreement and adjuvant sales.
In September, the FDA granted Emergency Use Authorization to&nbsp;Novavax&#8217;s COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705), for active immunization to prevent COVID-19 in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants" rel="noreferrer noopener">individuals aged 12 and older</a>.
The COVID-19 vaccine maker reported an EPS loss of 76 cents, up from a $1.26 loss a year ago, beating the consensus of 83 cents loss.
The net loss for the third quarter of 2024 was $121 million, compared to $131 million in the same period in 2023.
&#8220;Novavax continues to focus on our corporate growth strategy of driving value from additional business development activities and organic R&amp;D using our proven technology platform,&#8221; said John C. Jacobs, President and CEO of Novavax.
&#8220;In addition to progress on our other value drivers, this past quarter, we made significant progress defining our R&amp;D strategy as we look to expand beyond COVID-19 and influenza.&#8221;
Recently,&nbsp;the FDA removed the clinical hold on&nbsp;Novavax&#8217;s Investigational New Drug application for its COVID-19-influenza combination and stand-alone&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41878334/fda-gives-green-signal-to-novavaxs-covid-19-influenza-combo-vaccine-late-stage-trial" rel="noreferrer noopener">influenza vaccine candidates</a>.
Last week, Novavax and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health and Social Care, signed a Termination and Settlement Agreement and an amendment to resolve disputes over their updated COVID-19 vaccine supply contract from <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41782824/why-is-covid-19-vaccine-maker-novavax-stock-trading-lower-on-wednesday" rel="noreferrer noopener">July 1, 2022</a>.
Guidance: Novavax expects 2024 revenues of $650 million—$700 million, compared to prior guidance of $700 million—$800 million and a consensus of $761.5 million.
The company says full-year 2024 product sales guidance of $175 million-$225 million (vs. prior guidance of $275 million-$375 million) reflects approximately $100 million in APA dose deliveries in 1H 2024 and $75 million-$125 million in commercial market sales in 2H 2024.
Price Action: NVAX stock is down 11.20% at $8.01 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/24/11/41899460/boeing-lands-737-8-deal-with-avia-solutions-40-planes-now-40-more-to-follow" target="_blank" rel="noreferrer noopener">Boeing Lands 737-8 Deal With Avia Solutions: 40 Planes Now, 40 More To Follow</a></li>
</ul>
Photo by Vladimka production via Shutterstock

Guidance

Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls

Novavax shares are trading lower after the company lowered its 2024 revenue guidance to $650M-$700M, below prior guidance and analyst expectations.

Financial Framework
Novavax is updating its Full Year 2024 Financial Guidance and expects to achieve the following objectives.
Full Year 2024 Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
$ in millions
</td>
<td colspan="1" rowspan="1">
Prior
(as of Aug. 8, 2024)
</td>
<td colspan="1" rowspan="1">
Updated
(as of Nov. 12, 2024)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue</td>
<td colspan="1" rowspan="1">$700 - $800</td>
<td colspan="1" rowspan="1">$650 - $700</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Product Sales&nbsp;</td>
<td colspan="1" rowspan="1">$275 - $375</td>
<td colspan="1" rowspan="1">$175 - $225</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Licensing, Royalties and Other Revenue&nbsp;</td>
<td colspan="1" rowspan="1">$425</td>
<td colspan="1" rowspan="1">$475</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Combined R&amp;D and SG&amp;A</td>
<td colspan="1" rowspan="1">$700 - $750</td>
<td colspan="1" rowspan="1">$700 - $750</td>
</tr>
</tbody>
</table>
</figure>

Novavax Expects 2024 Total Revenues Of $650M-$700M Versus Prior Guidance Of $700M-$800M And Consensus Of $761.458M

Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.83) by 8.43 percent. The company reported quarterly sales of $84.51 million which beat the analyst consensus estimate of $65.78 million by 28.49 percent. This is a 54.80 percent decrease over sales of $186.99 million the same period last year.

Novavax Q3 2024 GAAP EPS $(0.76) Beats $(0.83) Estimate, Sales $84.51M Beat $65.78M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-12. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Novavax will report an earnings per share (EPS) of $-0.87.
Anticipation surrounds Novavax's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.37 in the last quarter, leading to a 0.68% drop in the share price on the following day.
Here's a look at Novavax's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.36</td>
<td>-1.06</td>
<td>-0.45</td>
<td>-1.83</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.99</td>
<td>-1.05</td>
<td>-1.47</td>
<td>-1.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>99.0%</td>
<td>12.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731358860_0.png" alt="eps graph" />
<h3>Tracking Novavax's Stock Performance</h3>
Shares of Novavax were trading at $8.91 as of November 08. Over the last 52-week period, shares are up 45.59%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/NVAX/earnings">To track all earnings releases for Novavax visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Novavax

Deep-pocketed investors have adopted a bullish approach towards Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVAX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Novavax. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 77% leaning bullish and 22% bearish. Among these notable options, 7 are puts, totaling $300,278, and 2 are calls, amounting to $146,900.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $9.0 to $40.0 for Novavax during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Novavax stands at 5805.6, with a total volume reaching 12,344.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novavax, situated within the strike price corridor from $9.0 to $40.0, throughout the last 30 days.
<h3>Novavax Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731354317_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$3.65</td>
<td>$3.65</td>
<td>$10.00</td>
<td>$84.6K</td>
<td>17.4K</td>
<td>1.2K</td>
</tr>
<tr>
<td>NVAX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.77</td>
<td>$0.66</td>
<td>$0.78</td>
<td>$10.00</td>
<td>$77.9K</td>
<td>10.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NVAX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$0.7</td>
<td>$0.69</td>
<td>$0.69</td>
<td>$9.50</td>
<td>$69.0K</td>
<td>1.0K</td>
<td>1.4K</td>
</tr>
<tr>
<td>NVAX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$10.00</td>
<td>$57.6K</td>
<td>17.4K</td>
<td>1.9K</td>
</tr>
<tr>
<td>NVAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$3.65</td>
<td>$3.65</td>
<td>$10.00</td>
<td>$44.8K</td>
<td>17.4K</td>
<td>1.3K</td>
</tr>
</tbody>
</table>

<h3>About Novavax</h3>
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
In light of the recent options history for Novavax, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Novavax</h3>
<ul>
<li>Currently trading with a volume of 11,712,916, the NVAX's price is up by 1.42%, now at $9.04. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<h3>What Analysts Are Saying About Novavax</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $25.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies has decided to maintain their Buy rating on Novavax, which currently sits at a price target of $25. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novavax, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Spotlight on Novavax: Analyzing the Surge in Options Activity

Shares of vaccine makers such as Moderna ($MRNA) and Novavax ($NVAX) are down on news that president-elect Donald Trump has nominated Robert F. Ken...

Moderna (MRNA) and Other Vaccine Stocks Fall on News of RFK Jr. Health Nomination

Vaccine stocks drop on concerns about RFK Jr. heading HHS

Vaccine stocks drop on concerns about RFK Jr. heading HHS (update)

B.Riley Financial analyst Mayank Mamtani has maintained their bullish stance on NVAX stock, giving a Buy rating on November 13. Mayank Mamtani's ra...

Strategic Transformation and Growth Prospects: Mayank Mamtani's Buy Rating on Novavax

An announcement from Novavax ( ($NVAX) ) is now available. Novavax, Inc. is set to update investors at the Jefferies London Healthcare Conference w...

Novavax to Present at Jefferies London Conference

Novavax, Inc. (NVAX) Jefferies London Healthcare Conference (Transcript)

CDC warns against a spike in COVID, flu cases

CDC warns of an imminent spike in COVID, flu cases

Johns Hopkins surgeon and writer Martin Makary is expected to be selected by President-elect Donald Trump to head the U.S. FDA, Reuters' Stephanie ...

Trump expected to pick Martin Makary to head FDA, Reuters reports

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President-...

Trump Trade: Trump Media considers developing crypto payment service

ABBV

BITF

BVNKF

BVNRY

CMXHF

CSLLY

SHOO

Press Releases

NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm

Legal

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024

U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

Novavax to Participate in Jefferies London Healthcare Conference

Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

Comments

Novavax

Vendite allo scoperto

Novavax (NASDAQ:NVAX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO